Abstract 1368: The impact of bevacizumab on combination low-dose afatinib and cetuximab therapy in lung cancer cells harboring activated EGFR mutations

Background. The combination of afatinib and cetuximab induced an unprecedented response in lung tumors harboring EGFR T790M in clinical trials (Cancer Discov. 2014). However, up to 20% of patients discontinued treatment due to adverse events, including skin rashes and diarrhea, and the median progression-free survival of the combination therapy was 4.7 months. There is clearly still room for improvement in the therapy. Bevacizumab, a key drug in...